(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
3 March 2011 (03.03.2011)

PCT

(10) International Publication Number
WO 2011/025927 A1

(51) International Patent Classification:
C07D 401/14 (2006.01) *A61K 31/506* (2006.01)
C07D 403/04 (2006.01) *A61P 35/00* (2006.01)

(21) International Application Number:
PCT/US2010/046930

(22) International Filing Date:
27 August 2010 (27.08.2010)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/238,073 28 August 2009 (28.08.2009) US
61/313,039 11 March 2010 (11.03.2010) US

(71) Applicants *(for all designated States except US)*: **IRM LLC** [US/—]; 131 Front Street, Hamilton, HM LX (BM). **NOVARTIS AG** [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **HUANG, Shenlin** [CN/US]; 5768 Cape Jewels Trail, San Diego, California 92130 (US). **JIN, Xianming** [US/US]; 3516 Sleeping Meadow Way, San Ramon, California 94582 (US). **LIU, Zuosheng** [CN/US]; 10280 Camino Ruiz, Apartment No. 45, San Diego, California 92121 (US). **POON, Daniel** [US/US]; 54 Lake Avenue, Piedmont, California 94611 (US). **TELLEW, John** [US/US]; 1340 Caminito Balada, La Jolla, California 92037 (US). **WAN, Yongqin** [CN/US]; 19 Santa Eugenia, Irvine, California 92026 (US). **WANG, Xing** [CN/US]; 16152 Avenida Venusto, No. 4, San Diego, California 92128 (US). **XIE, Yongping** [US/US]; 12596 Brickella Street, San Diego, California 92129 (US).

(74) Agents: **REID, Scott** et al.; Genomics Institute of the Novartis, Research Foundation, 10675 John Jay Hopkins Drive, San Diego, California 92121 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

— *with international search report (Art. 21(3))*

(54) **Title**: COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS





Figure 1



I

(57) **Abstract**: The invention provides a novel class of compounds of formula 1, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of B-Raf.

WO 2011/025927 A1